Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 250

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 250
---
 closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Expected Dividend—The expected dividend yield is assumed to be zero because the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. Expected Term—The Company estimates the expected term of its stock options granted to employees and non-employeedirectors using the simplified method, whereby, the expected term equals the average of the vesting term and the original.

| (2) | As of December 31, 2024, Dr. Castelein held options to purchase 117,727 shares of Company common 
 stock.                                                                                           |

| (3) | As of December 31, 2024, Dr. Dalal held options to purchase 117,727 shares of Company common stock 
 and 486 shares of common stock, respectively.                                                      |

| (4) | As of December 31, 2024, Ms. Reeve held options to purchase 109,146 shares of Company common stock. |

| (5) | As of December 31, 2024, Dr. Aghazadeh held options to purchase 110,209 shares of Company common 
 stock.                                                                                           |

| (6) | As of December 31, 2024, Dr. Hehenberger held options to purchase 110,209 shares of Company common 
 stock.                                                                                             |

| (7) | As of December 31, 2024, Mr. Maroun held options to purchase 133,999 shares of Company common stock. |

| (8) | As of December 31, 2024, Dr. Hirmand held options to purchase 105,038 shares of Company common stock. |

| (9) | As of December 31, 2024, Dr. Zhou held options to purchase 61,192 shares of Company common stock. |

- 173 -

EQUITY COMPENSATION PLAN INFORMATION Securities Authorized for Issuance Under Equity Compensation Plans We maintain our 2017 Stock Option and Incentive Plan, 2021 Plan, 2021 Employee Stock Purchase Plan (“2021 ESPP”), 2023 Inducement Equity Incentive Plan (“2023 Plan”), which was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c